|Bid||12.15 x 100|
|Ask||23.50 x 600|
|Day's Range||14.50 - 15.02|
|52 Week Range||12.89 - 19.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.42|
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding IRWD totaled $348 million.
NEW YORK, NY / ACCESSWIRE / February 16, 2018 / Ironwood Pharmaceuticals was a big winner on Thursday after reporting better than expected fourth quarter results. Shares of Teva also scored big gains after ...
The Cambridge, Massachusetts-based company said it had net income of 8 cents per share. Losses, adjusted for non-recurring gains, came to 14 cents per share. The results exceeded Wall Street expectations. ...
Ironwood Pharmaceuticals, Inc. , a commercial biotechnology company, today provided an update on its fourth quarter and full year 2017 results and recent business activities.
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Ironwood Pharmaceuticals Inc’s (NASDAQ:IRWD) track record on a high level, toRead More...
Ironwood Pharmaceuticals, Inc. today announced it will host its fourth quarter and full-year 2017 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2018.
NEW YORK, NY / ACCESSWIRE / January 25, 2018 / U.S. markets were mixed Wednesday as technology stocks pressured the S&P 500 and the Nasdaq lower, while the Dow rose on strength from the financial sector. ...
Ironwood Pharmaceuticals, Inc. and Allergan plc announced today that the companies have reached an agreement with wholly-owned subsidiaries of Sun Pharmaceutical Industries Ltd.
NEW YORK, NY / ACCESSWIRE / January 12, 2017 / Shares of both Agios Pharmaceuticals and Ironwood Pharmaceuticals saw big gains on Thursday with colossal trading volume, despite any catalyst to explain ...
Ironwood Pharmaceuticals, Inc. will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 11:30 a.m. Pacific Time / 2:30 p.m.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ironwood Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IRWD-US. Comparing the performance and risk of Ironwood Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.
Ironwood Pharmaceuticals, Inc. , a commercial biotechnology company, today announced the initiation of STRONG-SCD, a Phase II clinical trial evaluating once-daily IW-1701, an orally administered soluble guanylate cyclase stimulator, in patients with sickle cell disease.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ironwood Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Ironwood Pharmaceuticals, Inc. a score of 44. Our analysis is based on comparing Ironwood Pharmaceuticals, Inc. with the following peers – Progenics Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Nektar Therapeutics, Astrazeneca PLC Sponsored ADR, Sucampo Pharmaceuticals, Inc. Class A, Cumberland Pharmaceuticals Inc. and Synthetic Biologics, Inc. (PGNX-US, SGYP-US, ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ironwood Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.
The Cambridge, Mass.-based Ironwood unveiled top-line data from a pair of Phase 2a studies evaluating IW-1973 in patients that have type 2 diabetes and hypertension.
Ironwood Pharmaceuticals Inc. shares surged 3.5% in premarket trade Monday, after the company reported positive results in mid-stage trials of a treatment for diabetes with hypertension. The company said ...
Ironwood Pharmaceuticals, Inc. today announced encouraging top-line results from two Phase IIa studies of IW-1973, Ironwood’s lead investigational soluble guanylate cyclase stimulator, in patients with type 2 diabetes and hypertension.